Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

zirconium Zr 89 anti-TAA monoclonal antibody BAY3630942

A radioimmunoconjugate comprised of a monoclonal antibody directed against an as of yet undisclosed tumor-associated antigen (TAA) conjugated to the radioisotope zirconium Zr 89 (Zr89), with potential use as an imaging agent upon positron emission tomography/computed tomography (PET/CT). Upon administration of Zr89 anti-TAA monoclonal antibody BAY3630942, the antibody moiety specifically targets and binds to the TAA expressed on tumor cells. Upon binding, the radioisotope moiety is detected using PET, thereby allowing the imaging of TAA-expressing tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:89Zr-labeled anti-TAA monoclonal antibody BAY3630942
89Zr-labeled monoclonal antibody BAY3630942
Zr89 anti-TAA monoclonal antibody BAY3630942
Code name:BAY 3630942
BAY-3630942
BAY3630942
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search